

# Benefit of Echocardiography in Patients With *Staphylococcus aureus* Bacteremia at Low Risk of Endocarditis

George S. Heriot,<sup>1,2,3</sup> Steven Y. C. Tong,<sup>2,3</sup> Allen C. Cheng,<sup>1,4,5</sup> and Danny Liew<sup>1</sup>

<sup>1</sup>School of Public Health and Preventative Medicine, Monash University Victoria, Australia <sup>2</sup>Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia; <sup>3</sup>Menzies School of Health Research, Royal Darwin Hospital, Northern Territory, Australia; <sup>4</sup>Department of Infectious Diseases and <sup>5</sup>Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Victoria, Australia

**Background.** The risk of endocarditis among patients with *Staphylococcus aureus* bacteremia is not uniform, and a number of different scores have been developed to identify patients whose risk is less than 5%. The optimal echocardiography strategy for these patients is uncertain.

**Methods.** We used decision analysis and Monte Carlo simulation using input parameters taken from the existing literature. The model examined patients with *S aureus* bacteremia whose risk of endocarditis is less than 5%, generally those with nosocomial or healthcare-acquired bacteremia, no intracardiac prosthetic devices, and a brief duration of bacteremia. We examined 6 echocardiography strategies, including the use of transesophageal echocardiography, transthoracic echocardiography, both modalities, and neither. The outcome of the model was 90-day survival.

**Results.** The optimal echocardiography strategy varied with the risk of endocarditis and the procedural mortality associated with transesophageal echocardiography. No echocardiography strategy offered an absolute benefit in 90-day survival of more than 0.5% compared with the strategy of not performing echocardiography and treating with short-course therapy. Strategies using transesophageal echocardiography were never preferred if the mortality of this procedure was greater than 0.5%.

**Conclusions.** In patients identified to be at low risk of endocarditis, the choice of echocardiography strategy appears to exert a very small influence on 90-day survival. This finding may render test-treatment trials unfeasible and should prompt clinicians to focus on other, more important, management considerations in these patients.

**Keywords.** bacteremia; echocardiography; endocarditis; selection criteria; *Staphylococcus aureus*.

*Staphylococcus aureus* bacteremia (SAB) is complicated by endocarditis in up to 18%–25% of unselected cases [1, 2], although the prevalence of endocarditis among these patients is not uniform and can be estimated using a variety of clinical and microbiological predictors [3]. Several studies have now reported criteria able to identify patients at very low risk (less than 5%) of endocarditis [4]. Although these studies vary in size, methodology, and the exact criteria used, it appears that patients at very low risk of endocarditis can be identified by day 3–5 after the onset of bacteremia, before any echocardiographic assessment, using clinical and microbiological criteria. In general, these patients have (1) nosocomial, healthcare-associated nonnosocomial, or central line-associated bacteremia, (2) a brief duration of bacteremia (less than 48–72 hours), and (3) no intracardiac prosthetic

device (prosthetic heart valves or cardiac rhythm management devices). A detailed description of this literature and its limitations can be found in our previous systematic review [4]. In particular, we refer readers to Table 1 in the previous review (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751065/table/T1>) for a summary of the various low-risk criteria sets.

Although current guidelines suggest that transesophageal echocardiography (TEE) is required for most, if not all, patients with SAB [5, 6], it remains uncertain whether this recommendation applies to very low-risk patients. Our previous work examining the benefit of TEE in patients with SAB suggested that TEE may be warranted in all patients with a risk of endocarditis above 1% [7], although this estimate did not examine the magnitude of the benefit of TEE or the role of transthoracic echocardiography (TTE).

The aim of this study was (1) to extend our previous modeling work to examine echocardiography strategies involving TTE and (2) to estimate the absolute 90-day survival resulting from various echocardiography strategies to inform the design of future trials in this area.

## METHODS

We used decision analysis [8] with Monte Carlo simulation [9] to examine the effect of various echocardiography strategies

Received 12 October 2018; editorial decision 4 November 2018; accepted 22 November 2018.  
 Correspondence: D. Liew, PhD, School of Public Health and Preventative Medicine, Monash University Level 4, 553 St Kilda Road, Melbourne, VIC 3004 ([danny.liew@monash.edu](mailto:danny.liew@monash.edu)).

Open Forum Infectious Diseases®

© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)  
 DOI: 10.1093/ofid/ofy303

on the 90-day survival of patients with SAB assessed as having less than 5% probability of endocarditis. The binary outcome of 90-day survival was chosen to reflect the recognized outcome measures of bacteremia trials [10].

**Model Structure**

Each patient in the model had SAB without clinical features of endocarditis (eg, new murmur, heart failure, emboli, or immunological phenomena) and an estimated probability of endocarditis of less than 5% based on the criteria outlined above. Such patients were considered to have 1 of 3 mutually exclusive static disease states: uncomplicated SAB, clinically occult *S aureus* left-sided native valve endocarditis (NVIE) without perivalvular abscess, and NVIE with perivalvular abscess formation.

We examined 6 echocardiography strategies: TEE as the only study (abbreviated “TEE”); TTE as the only study (“TTE”); TTE first followed by TEE only if the TTE is negative for endocarditis (“TEE|TTE-”); TTE first followed by TEE only if the TTE is positive for endocarditis (“TEE|TTE+”); short-course antibiotic treatment (2 weeks) without echocardiography (“NE2”); and long-course antibiotic treatment (6 weeks) without echocardiography (“NE6”). We did not include the strategy of performing both TTE and TEE, because under the assumptions described below this strategy would have identical results to the TEE strategy.

Echocardiography results (for the 4 strategies in which echocardiography was performed) conformed to these same 3 states, with the correlation between the actual disease state and the echocardiographic result being dependent on the diagnostic performance of each echocardiography strategy. Transthoracic echocardiography and TEE were not assumed to be independent tests given the similarities between the 2 procedures. The degree

of statistical covariance between these tests was described as the percentage of the maximal covariance allowed by the observed diagnostic performance statistics [11].


Patient treatment was based on the results of echocardiography alone. Patients thought not to have endocarditis received 2 weeks of parenteral anti-staphylococcal therapy; those thought to have uncomplicated NVIE received 6 weeks of parenteral anti-staphylococcal therapy; and those thought to have NVIE complicated by perivalvular abscess received 6 weeks of parenteral anti-staphylococcal therapy and cardiac surgery (assumed to be valve replacement). If a patient underwent both TTE and TEE, treatment was based on the results of the TEE. The 2 strategies without echocardiography resulted in all patients receiving antibiotic therapy for the duration specified without surgery for perivalvular abscess.

A decision tree summarizing the model is presented in Figure 1. Patients were assumed not to manifest clinical signs of endocarditis during treatment, such that interventions for endocarditis (antibiotic prolongation or surgery) were based solely on the echocardiography results. Likewise, no patient underwent surgery for indications other than clinically occult perivalvular abscess. Patients were also assumed not to have any other sites of staphylococcal infection warranting prolonged treatment.

Survival outcomes in the model were additive. The expected survival resulting from any given strategy was the sum of the products of each possible permutation’s probability and its respective expected survival.

**Model Inputs**

Parameter estimates and error distributions were identified from the medical literature published before November 16, 2017 using



**Figure 1.** Summary decision tree for the model. TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.

a stepwise search strategy, as described in a previous publication [7]. Additional inputs required for this investigation included the diagnostic performance of TTE compared with TEE for the detection of clinically occult *S aureus* NVIE and the statistical covariance (non-independence) of TTE and TEE.

### Monte Carlo Simulation

For each specific input scenario, we conducted a 10000-patient Monte Carlo simulation to estimate the 90-day survival resulting from each of the 6 strategies. Two-variable strategy analyses were built from multiple 1000 patient simulations. The decision model and the Monte Carlo simulations were constructed using Microsoft Excel (Microsoft Corporation, Redmond, WA).

### Statistical Analysis

Due to the dominant effect of the prevalence of endocarditis in the model and the previously noted broad uncertainty regarding the procedural mortality of TEE [7], we planned to present the result of the decision model primarily as a strategy analysis based on these 2 variables. We also examined the absolute benefit of each of the strategies above NE2 (as the simplest and

least burdensome option) in 2 informative scenarios. The first examined patients with a VIRSTA score [3] of less than 3 points (risk of endocarditis 1.8%, 95% confidence interval 1.0%–3.6%, assuming a prevalence of 18% among unselected patients with SAB [2]) and a TEE-associated mortality of 1.0%. This scenario represents the lowest expected survival benefit of any echocardiography strategy because it is not currently possible to reliably identify patients at any lower risk of endocarditis [4]. The second scenario examined patients with a 5% risk of endocarditis and a TEE-associated mortality of 0.01% (the largest expected benefit within the model envelope).

### Literature Review and Model Inputs

The majority of model inputs were sourced from a previous review [7]. Estimates of the diagnostic performance of TTE compared with TEE were drawn from a recent systematic review specifically addressing this issue [12]. No studies were identified that presented data allowing an estimate of the statistical covariance of TTE and TEE. The inputs and their associated sampling distributions are presented in Table 1.

**Table 1. Parameter Estimates, Error Distributions, and Sources**

Definition	Estimate	Range or 95% Confidence Interval	Sampling Distribution	References
<b>Probability of Disease</b>				
Prevalence of clinically occult endocarditis in patients with apparently uncomplicated SAB and no intracardiac prosthetic device	Variable	0%–5%		[4, 13]
Prevalence of perivalvular abscess among patients with clinically occult NVIE	15%	10%–20%	Triangular	[14–18]
Probability of relapse if clinically occult left-sided NVIE treated with 2 weeks of parenteral antibiotic therapy	60%	40%–80%	Triangular	[19–27]
<b>Diagnostic Performance of TEE</b>				
Sensitivity of TEE for clinically occult NVIE	96%	92%–99%	Triangular	[5, 29–31]
Specificity of TEE for clinically occult NVIE	90%	90%–95%	Triangular	[5, 29–31]
Sensitivity of TEE for perivalvular abscess in NVIE	75%	40%–90%	Triangular	[17, 18, 32–34]
Specificity of TEE for perivalvular abscess in NVIE	98%	96%–100%	Triangular	[16, 18, 32–34]
<b>Diagnostic Performance of TTE</b>				
Apparent sensitivity of TTE for occult NVIE (compared with TEE)	58%	53%–62%	Beta	[12]
Apparent specificity of TTE for occult NVIE	92%	91%–93%	Beta	[12, 26, 27]
Apparent sensitivity of TTE for perivalvular abscess	48%	29%–67%	Beta	[12]
Apparent specificity of TTE for perivalvular abscess	100%	99%–100%	Beta	[12]
%Maximum statistical covariance between TTE and TEE	25%	0%–50%	Triangular	No data
<b>Survival Estimates for Various Diseases States</b>				
90-day survival of patients with apparently uncomplicated SAB	80%	76%–83%	Beta	[35]
Excess mortality associated with diagnosed and treated NVIE	15%	10%–25%	Triangular	[36–38]
Additional mortality associated with relapsed partially treated NIVE	15%	12%–17%	Triangular	[39, 40]
Excess mortality associated with diagnosed and treated perivalvular abscess in NVIE	15%	0%–30%	Triangular	[14, 16, 1–43]
Additional mortality if perivalvular abscess initially goes unrecognized	15%	0%–30%	Triangular	[14, 16, 41–43]
<b>Risks Associated With Testing and Treatment</b>				
Excess mortality due to the procedures required for TEE	Variable	0.01%–1%		[44–47]
Excess mortality due to the procedures required for TTE	0%			Assumed
Excess mortality due to adverse drug events in weeks 2–6 of therapy	0.2%	0%–0.7%	Beta	[48, 49]
Excess mortality due to line infection arising in weeks 2–6 of therapy	0.3%	0.1%–0.8%	Beta	[50–61]
Excess mortality due to cardiac surgery for perivalvular abscess	5%	3%–9%	Triangular	[62, 63]

Abbreviations: NVIE, native valve endocarditis; SAB, *Staphylococcus aureus* bacteremia; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.

## RESULTS

In general, multiple independent sources in general agreement with each other were found for each of these parameters, with 3 exceptions: (1) the excess mortality associated with the procedure of TEE; (2) the likelihood of relapse if unrecognized clinically occult *S aureus* NVIE were to be treated with short-course antibiotic therapy; and (3) the statistical covariance (non-independence) of TTE and TEE. Our rationale for the ranges examined in the sensitivity analyses is presented in the [Supplementary Materials](#).

### Strategy Analysis


The preferred echocardiography strategy for 90-day survival after apparently uncomplicated SAB varied depending on the probability of occult endocarditis and the procedural risk of TEE ([Figure 2](#)). Over the ranges tested, only 2 of the 6 strategies were not preferred at some combination of these inputs. In general, at low TEE procedural risk (<0.1% mortality), the choice appeared to be between TEE and TEE|TTE+. At high TEE procedural risk (>0.5% mortality), strategies utilizing TEE were never preferred.

Given the uncertainty in the literature regarding the relapse risk of undertreated clinically occult endocarditis and the


statistical covariance of TTE and TEE, we conducted additional sensitivity analyses examining the effect of altering our chosen values for these uncertain parameters (see [Supplementary Figures S1–S4](#)). Assuming universal relapse of occult endocarditis treated for only 2 weeks resulted in a lower threshold at which TEE was preferred over TEE|TTE+. A more complex effect was seen when the errors of TTE and TEE were assumed to be highly correlated—the consequent reduction in the corrected diagnostic performance of TTE and the lower informational value of combination strategies led to the TTE-based strategies being preferred across a very small range of the model envelope.

### Absolute Benefit of Echocardiography Strategies in Specific Scenarios

The median 90-day survival benefit of any echocardiography strategy compared with NE2 remained less than 0.5%, even at an endocarditis risk of 5%. As seen in [Figure 3A](#), the maximal expected survival benefit for the TEE strategy compared with NE2 was +0.43% (95% confidence interval, +0.28%–0.58%) at 90 days, corresponding to a number-needed-to-test of 233. The maximal harm for any strategy within the clinically observable model envelope was an excess 0.87% mortality (95% confidence interval, 0.69%–1.06%) seen for the TEE strategy when the mortality from TEE was set to 1% and the risk of endocarditis was set to 1.8% ([Figure 3B](#)). Although it is only preferred



**Figure 2.** Preferred echocardiography strategy for patients with *Staphylococcus aureus* bacteremia at low risk of endocarditis. Each box represents 1000 simulations with a flat sampling distribution across both the x and y intervals. Large symbols denote where a single strategy was preferred in ≥90% of simulations; small symbols denote where a strategy was preferred in 75%–90% of simulations. Empty regions denote where no single strategy was preferred in at least 75% of simulations. TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.



**Figure 3.** Absolute benefit of various echocardiography strategies for 90-day survival compared with no echocardiography and treatment with short-course therapy (NE2). Boxes denote the 25th, 50th, and 75th percentile values, and the whiskers contain the 95% confidence interval. (A) considers patients with a 5% risk of endocarditis and a transesophageal echocardiography (TEE)-associated mortality risk of 0.01%. (B) considers patients with a VIRSTA score of <3 points (risk of endocarditis 1.8%) and a 1% TEE-associated mortality risk. These points respectively represent the highest and lowest expected survival benefits of echocardiography within the clinically observable portion of the strategy analysis presented in Figure 2. TTE, transthoracic echocardiography.


over the other echocardiography strategies at high TEE procedural mortality, the TTE strategy appeared to retain a net benefit (albeit marginal) across the modeled range of endocarditis probabilities.

When considering patients with a VIRSTA score of less than 3 points (risk of endocarditis, 1.8%; 95% confidence interval, 1.0%–3.6%) at the traditional estimate for TEE mortality (0.01%), the TEE strategy still offered the best 90-day survival, but the absolute benefit compared with NE2 was only 0.12% (95% confidence interval, –0.02%–0.30%), corresponding to a number-needed-to-test of more than 800 patients (Figure 4).

## DISCUSSION

The preferred echocardiography strategy for patients with SAB who are at low risk of endocarditis varies depending on the absolute endocarditis risk and the procedural risks of TEE, but the magnitude of the effect of any strategy on 90-day survival is small. We believe this result has implications for clinicians making decisions regarding the management of these patients as well as for the design of future trials examining the optimal management of patients with SAB.

The small absolute benefit of echocardiography suggested by the results of our modeled analysis is not unexpected. Although it is conceivable that incidental noninfectious echocardiographic findings may be of help to clinicians managing these patients, the benefit of echocardiography in this setting is



**Figure 4.** Absolute benefit of various echocardiography strategies for 90-day survival compared with no echocardiography and treatment with short course therapy (NE2) for a patient with a VIRSTA score [3] of less than 3 points (risk of endocarditis 1.8%; 95% confidence interval, 1.0–3.6%) at a transesophageal echocardiography (TEE)-associated mortality risk of 0.01%. Boxes denote the 25th, 50th, and 75th percentile values, and the whiskers contain the 95% confidence interval. TTE, transthoracic echocardiography.



largely limited to the detection of occult endocarditis. As such, regardless of the degree to which patients with endocarditis might benefit from its identification and treatment, these benefits are restricted to the subgroup of patients with the disease. In other words, the absolute benefit of disease-specific testing is necessarily less than the prevalence of disease. In this study, the low prevalence of endocarditis among modeled patients translates to an even smaller benefit from echocardiography.

The results of our analysis are generally consistent with 2 previous modeling studies examining the role of echocardiography in patients at risk of endocarditis. Rosen et al [22] examined the cost-effectiveness of the TEE strategy compared with no echocardiography (NE2 and NE6) in patients with a 6.1% prevalence of endocarditis (the authors' estimate of the prevalence of endocarditis among patients with central-line associated SAB). Even with assumptions favorable to TEE (very low TEE-related procedural mortality, high TEE specificity, and uncomplicated local phlebitis as the only adverse effect of unnecessary prolonged antibiotics), the authors estimated that performing TEE would obtain, on average, an additional 16 quality-adjusted life days over short-course antibiotic therapy alone in their base case scenario. Due to its low modeled cost, TEE was found to be cost effective (at a threshold of USD 50 000/QALY in 1997) for patients with a risk of endocarditis above 1.7%.

Heidenreich et al [64] performed a cost-effectiveness study of echocardiography (TEE, TTE, or TEE|TTE-) in patients suspected of endocarditis due to any organism. Using assumptions that are not necessarily applicable to patients with SAB (most notably a low incidence of non-endocarditis mortality), the authors estimated a benefit in overall nonadjusted survival of 41 days from the use of TEE over short-course treatment in patients at a 20% risk of endocarditis. Although a utility-only threshold was not reported, none of the echocardiography strategies were reported to be cost effective for patients whose risk of endocarditis was less than 2%.

As has been noted previously [65], the ability of a diagnostic testing strategy to affect the outcomes of only a small segment of the population to which it is applied has major implications for the feasibility of conducting randomized test-treatment trials. The structure and results of our model can be used to examine the sample sizes required in a trial comparing echocardiography strategies in patients with SAB at low risk of endocarditis in which the outcome is 90-day survival. For example, for uncomplicated patients at a 1.8% risk of endocarditis (the point of apparent clinical equipoise [66]), a trial designed to demonstrate noninferiority for the binary outcome of 90-day survival for the NE2 strategy compared with TEE with a delta of 1.8% and standard power ( $\alpha$  0.05 2-sided,  $\beta$  0.90) would require between 7948 and 19708 participants, depending on the estimated procedural mortality of TEE—more than 10 times the size of the largest *S aureus* trial conducted to date [67]. Using a wider noninferiority margin would certainly reduce the

required sample size, but it would render the trial redundant because the failure to diagnose endocarditis by echocardiography cannot contribute excess mortality in patients without the disease. Alternative approaches to assessing the value of echocardiography in low-risk patients, such as cost-effectiveness modeling or clinical quality registries, may be more feasible than comparative test-treatment trials.

From a practical perspective, the results of our study should help clinicians understand where decisions regarding echocardiographic screening of patients at low risk of endocarditis should fit among the numerous other management priorities in SAB. In the first place, it should be evident that accurate stratification of patients by risk of endocarditis using any of a number of published criteria [4] is much more important than the choice of echocardiography strategy in those predicted to be at low risk. Likewise, in patients at low risk of endocarditis, more attention and effort should be directed towards optimizing interventions expected to be broadly beneficial (eg, appropriate antimicrobial therapy and expeditious source control) than to those with the potential to benefit only a small fraction of patients (echocardiography). For patients at the lowest risk of endocarditis, the survival benefit of any echocardiography strategy compared with empiric short-course therapy is marginal at best. Although many clinicians may not be ready to remove echocardiography entirely from management algorithms, our results suggest that the mortality benefit of pursuing TEE for patients at low risk of endocarditis is not of clinical significance compared with TTE-based strategies. This finding may have particular relevance in settings where TEE is not easily accessible.

### Limitations

Our analysis has a number of unavoidable limitations that arise from the structure of the model and the uncertainty of its inputs. We have made several assumptions within the structure of the model that generally favor the performance of echocardiography, including that occult NVIE never manifests clinically other than by relapse after the cessation of parenteral antimicrobial therapy (crossovers to endocarditis treatment would be expected to reduce any differences in survival) and that no patient with apparently uncomplicated SAB receives more than 14 days of parenteral therapy for any indication other than echocardiographically documented endocarditis (en passant treatment of unrecognized endocarditis would reduce the expected incidence of relapse). We also assumed that echocardiography results have no prognostic impact (ie, that patients with endocarditis have the same prognosis regardless of the echocardiographic demonstration of endocardial involvement), although recent evidence would suggest that this may not be the case [68]. These assumptions are clinically unrealistic but have been used in the model to maximize the apparent benefit of echocardiography over clinical observation alone; there are few available data to guide how often these assumptions may be violated in clinical practice.

Our model also only examined the binary outcome of 90-day survival and did not include nonfatal morbidity arising from endocarditis or its treatment. Due to the low proportion of patients with endocarditis within the model envelope, the addition of morbidity might be expected to be more detrimental to strategies involving more intervention (TEE or extended antibiotic therapy) because the additional outcomes would apply to a larger fraction of patients than are at risk of morbidity from unrecognized endocarditis.

The results of any decision analysis are highly dependent on the accuracy of the input parameters. We needed to identify estimates for 22 separate inputs from existing literature that was at times very diffuse and oblique. We were able to find multiple sources in rough agreement for all but the 3 parameters noted above, all of which have been subjected to sensitivity analyses across a wide range of values. Although the preferred echocardiography strategy did appear sensitive to varying inputs (see the unresolved sections of Figure 1 and Supplementary Figures S1 and S3), the infrequency of endocarditis within the model envelope minimized the effect of parameter uncertainty on all estimates of absolute 90-day survival.

## CONCLUSIONS

In conclusion, a variety of echocardiography strategies may offer a survival advantage to patients with SAB at a low risk of endocarditis, but none results in an absolute risk reduction in 90-day mortality of more than 0.5%. This small benefit may render test-treatment trials unfeasible, and it should prompt clinicians to focus on other, more important, management considerations in these patients.

## Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

## Acknowledgments

**Financial support.** This work was funded by the Australian Government Research Training Program and the Monash University Faculty of Medicine, Nursing and Health Sciences (to G. S. H.) and an Australian National Health and Medical Research Council Career Development Fellowship (no. 1065736; to S. Y. C. T.). S. Y. C. T. is the holder of Australian National Health and Medical Research Council grants including for the performance of a randomized controlled trial in the treatment of methicillin-resistant *Staphylococcus aureus*.

**Potential conflicts of interest.** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

## References

1. Incani A, Hair C, Purnell P, et al. *Staphylococcus aureus* bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis. *Eur J Clin Microbiol Infect Dis* **2013**; 32:1003–8.
2. Heriot GS, Cheng AC, Tong SY, Liew D. Clinical predictors and prediction rules to estimate initial patient risk for infective endocarditis in *Staphylococcus aureus*

bacteraemia: attention must be paid to the reference standard. *Clin Microbiol Infect* **2018**; 24:314–6.

3. Tubiana S, Duval X, Alla F, et al. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with *Staphylococcus aureus* bacteremia. *J Infect* **2016**; 72:544–53.
4. Heriot GS, Cronin K, Tong SYC, et al. Criteria for identifying patients with *Staphylococcus aureus* bacteremia who are at low risk of endocarditis: a systematic review. *Open Forum Infect Dis* **2017**; 4:ofx261.
5. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association of Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* **2015**; 36:3075–128.
6. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. *Circulation* **2015**; 132:1435–86.
7. Heriot GS, Tong SY, Cheng AC, Liew D. What risk of endocarditis is low enough to justify the omission of transoesophageal echocardiography in *Staphylococcus aureus* bacteraemia? A narrative review. *Clin Microbiol Infect* **2018**. doi:10.1016/j.cmi.2018.03.027
8. Lilford RJ, Pauker SG, Braunholtz DA, Chard J. Decision analysis and the implementation of research findings. *BMJ* **1998**; 317:405–9.
9. Briggs AH. Handling uncertainty in cost-effectiveness models. *Pharmacoeconomics* **2000**; 17:479–500.
10. Harris PNA, McNamara JF, Lye DC, et al. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. *Clin Microbiol Infect* **2017**; 23:533–41.
11. Vacek PM. The effect of conditional dependence on the evaluation of diagnostic tests. *Biometrics* **1985**; 41:959–68.
12. Bai AD, Steinberg M, Showler A, et al. Diagnostic accuracy of transthoracic echocardiography for infective endocarditis findings using transesophageal echocardiography as the reference standard: a meta-analysis. *J Am Soc Echocardiogr* **2017**; 30:639–646.e8.
13. Bai AD, Agarwal A, Steinberg M, et al. Clinical predictors and clinical prediction rules to estimate initial patient risk for infective endocarditis in *Staphylococcus aureus* bacteraemia: a systematic review and meta-analysis. *Clin Microbiol Infect* **2017**; 23:900–6.
14. Anguera I, Miro JM, Cabell CH, et al. Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the International Collaboration on Endocarditis Merged Database. *Am J Cardiol* **2005**; 96:976–81.
15. Anguera I, Miro JM, Evangelista A, et al. Periannular complications in infective endocarditis involving native aortic valves. *Am J Cardiol* **2006**; 98:1254–60.
16. Choussat R, Thomas D, Isnard R, et al. Perivalvular abscesses associated with endocarditis; clinical features and prognostic factors of overall survival in a series of 233 cases. Perivalvular Abscesses French Multicentre Study. *Eur Heart J* **1999**; 20:232–41.
17. Arnett EN, Roberts WC. Valve ring abscess in active infective endocarditis. Frequency, location, and clues to clinical diagnosis from the study of 95 necropsy patients. *Circulation* **1976**; 54:140–5.
18. Hill EE, Herijgers P, Claus P, et al. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. *Am Heart J* **2007**; 154:923–8.
19. Mansur AJ, Dal Bó CM, Fukushima JT, et al. Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis. *Am Heart J* **2001**; 141:78–86.
20. Fernández-Hidalgo N, Almirante B, Tornós P, et al. Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital. *Clin Microbiol Infect* **2012**; 18:E522–30.
21. Jernigan JA, Farr BM. Short-course therapy of catheter-related *Staphylococcus aureus* bacteremia: a meta-analysis. *Ann Intern Med* **1993**; 119:304–11.
22. Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated *Staphylococcus aureus* bacteremia. *Ann Intern Med* **1999**; 130:810–20.
23. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated *Staphylococcus aureus* bacteremia. *Clin Infect Dis* **2005**; 40:695–703.
24. Joseph JP, Meddows TR, Webster DP, et al. Prioritizing echocardiography in *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother* **2013**; 68:444–9.
25. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to *Staphylococcus aureus* bacteremia among patients receiving long-term hemodialysis. *Infect Control Hosp Epidemiol* **2005**; 26:534–9.

26. Khatib R, Sharma M. Echocardiography is dispensable in uncomplicated *Staphylococcus aureus* bacteremia. *Medicine (Baltimore)* **2013**; *92*:182–8.
27. Rasmussen RV, Høst U, Arpi M, et al. Prevalence of infective endocarditis in patients with *Staphylococcus aureus* bacteraemia: the value of screening with echocardiography. *Eur J Echocardiogr* **2011**; *12*:414–20.
28. Shapiro SM, Young E, De Guzman S, et al. Transesophageal echocardiography in diagnosis of infective endocarditis. *Chest* **1994**; *105*:377–82.
29. Erbel R, Rohmann S, Drexler M, et al. Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study. *Eur Heart J* **1988**; *9*:43–53.
30. Shively BK, Gurule FT, Roldan CA, et al. Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis. *J Am Coll Cardiol* **1991**; *18*:391–7.
31. Mügge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. *J Am Coll Cardiol* **1989**; *14*:631–8.
32. Daniel WG, Mügge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. *N Engl J Med* **1991**; *324*:795–800.
33. Cicioni C, Di Luzio V, Di Emidio L, et al. Limitations and discrepancies of transthoracic and transoesophageal echocardiography compared with surgical findings in patients submitted to surgery for complications of infective endocarditis. *J Cardiovasc Med (Hagerstown)* **2006**; *7*:660–6.
34. Koo HJ, Yang DH, Kang JW, et al. Demonstration of infective endocarditis by cardiac CT and transoesophageal echocardiography: comparison with intra-operative findings. *Eur Heart J Cardiovasc Imaging* **2018**; *19*:199–207.
35. Su CH, Chang SC, Yan JJ, et al. Excess mortality and long-term disability from healthcare-associated *Staphylococcus aureus* infections: a population-based matched cohort study. *PLoS One* **2013**; *8*:e71055.
36. Brown J, Brown K, Forrest A. Vancomycin AUC<sub>24</sub>/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant *Staphylococcus aureus* and its association with attributable mortality during hospitalization. *Antimicrob Agents Chemother* **2012**; *56*:634–8.
37. Le Moing V, Alla F, Doco-Lecompte T, et al. *Staphylococcus aureus* bloodstream infection and endocarditis—a prospective cohort study. *PLoS One* **2015**; *10*:e0127385.
38. Kaasch AJ, Barlow G, Edgeworth JD, et al. *Staphylococcus aureus* bloodstream infection: a pooled analysis of five prospective, observational studies. *J Infect* **2014**; *68*:242–51.
39. Albertson J, McDanel JS, Carnahan R, et al. Determination of risk factors for recurrent methicillin-resistant *Staphylococcus aureus* bacteremia in a Veterans Affairs healthcare system population. *Infect Control Hosp Epidemiol* **2015**; *36*:543–9.
40. Chu VH, Sexton DJ, Cabell CH, et al. Repeat infective endocarditis: differentiating relapse from reinfection. *Clin Infect Dis* **2005**; *41*:406–9.
41. Chan KL. Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess. *CMAJ* **2002**; *167*:19–24.
42. Lerakis S, Robert Taylor W, Lynch M, et al. The role of transesophageal echocardiography in the diagnosis and management of patients with aortic perivalvular abscesses. *Am J Med Sci* **2001**; *321*:152–5.
43. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. *JAMA* **2003**; *290*:3207–14.
44. Daniel WG, Erbel R, Kasper W, et al. Safety of transesophageal echocardiography. A multicenter survey of 10,419 examinations. *Circulation* **1991**; *83*:817–21.
45. Khandheria BK, Seward JB, Bailey K, et al. Safety of transesophageal echocardiography: experience with 2070 consecutive procedures. *J Am Coll Cardiol* **1991**; *17*:A20.
46. Min JK, Spencer KT, Furlong KT, et al. Clinical features of complications from transesophageal echocardiography: a single-center case series of 10,000 consecutive examinations. *J Am Soc Echocardiogr* **2005**; *18*:925–9.
47. Klein AL, Grimm RA, Murray RD. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med* **2001**; *344*:1411–20.
48. Blumenthal KG, Youngster I, Rabideau DJ, et al. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. *J Allergy Clin Immunol* **2015**; *136*:1288–94.e1.
49. Barr DA, Semple L, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. *Int J Antimicrob Agents* **2012**; *39*:407–13.
50. Htin AK, Friedman ND, Hughes A, et al. Outpatient parenteral antimicrobial therapy is safe and effective for the treatment of infective endocarditis: a retrospective cohort study. *Intern Med J* **2013**; *43*:700–5.
51. Larioza J, Heung L, Girard A, Brown RB. Management of infective endocarditis in outpatients: clinical experience with outpatient parenteral antibiotic therapy. *South Med J* **2009**; *102*:575–9.
52. Cervera C, del Río A, García L. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. *Enferm Infecc Microbiol Clin* **2011**; *29*:587–92.
53. McMahon JH, O'keeffe JM, Grayson ML; Victorian Hith Outcomes Study Group. Is hospital-in-the-home (HITH) treatment of bacterial endocarditis safe and effective? *Scand J Infect Dis* **2008**; *40*:40–3.
54. Amodeo MR, Clulow T, Lainchbury J, et al. Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. *J Infect* **2009**; *59*:387–93.
55. Tokars JL, Cookson ST, McArthur MA, et al. Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy. *Ann Intern Med* **1999**; *131*:340–7.
56. Baharoun S, Almodaimeg H, Al Watban H, et al. Home intravenous antibiotics in a tertiary care hospital in Saudi Arabia. *Ann Saudi Med* **2011**; *31*:457–61.
57. Kieran J, O'Reilly A, Parker J, et al. Self-administered outpatient parenteral antimicrobial therapy: a report of three years experience in the Irish healthcare setting. *Eur J Clin Microbiol Infect Dis* **2009**; *28*:1369–74.
58. Upton A, Ellis-Pegler RB, Woodhouse A. Outpatient Parenteral Antimicrobial Therapy (OPAT): a review of experience at Auckland Hospital. *N Z Med J* **2004**; *117*:U1020.
59. Ziegler MJ, Pellegrini DC, Safdar N. Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis. *Infection* **2015**; *43*:29–36.
60. Tedja R, Gordon SM, Fatica C, Fraser TG. The descriptive epidemiology of central line-associated bloodstream infection among patients in non-intensive care unit settings. *Infect Control Hosp Epidemiol* **2014**; *35*:164–8.
61. Aslam S, Vaida F, Ritter M, Mehta RL. Systematic review and meta-analysis on management of hemodialysis catheter-related bacteremia. *J Am Soc Nephrol* **2014**; *25*:2927–41.
62. Martínez-Sellés M, Muñoz P, Arnáiz A, et al. Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. *Int J Cardiol* **2014**; *175*:133–7.
63. David TE, Gavra G, Feindel CM, et al. Surgical treatment of active infective endocarditis: a continued challenge. *J Thorac Cardiovasc Surg* **2007**; *133*:144–9.
64. Heidenreich PA, Masoudi FA, Maini B, et al. Echocardiography in patients with suspected endocarditis: a cost-effectiveness analysis. *Am J Med* **1999**; *107*:198–208.
65. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. *BMJ* **2012**; *344*:e686.
66. Kaasch AJ, Jung N. Editorial commentary: transesophageal echocardiography in *Staphylococcus aureus* bloodstream infection—always needed? *Clin Infect Dis* **2015**; *61*:29–30.
67. Thwaites GE, Scarborough M, Szubert A. Adjunctive rifampicin for *Staphylococcus aureus* bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* **2018**; *391*:668–78.
68. Vicent L, Saldívar HG, Bouza E, et al. Prognostic implications of a negative echocardiography in patients with infective endocarditis. *Eur J Intern Med* **2018**; *52*:40–8.